Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.11M | -5.05M | -5.50M | -8.18M | -7.52M |
| Total Depreciation and Amortization | 4.00K | 12.00K | 41.00K | 0.00 | 2.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.28M | -141.00K | 598.00K | 2.92M | 1.95M |
| Change in Net Operating Assets | 2.39M | 1.31M | -1.18M | 1.73M | -1.03M |
| Cash from Operations | -2.44M | -3.87M | -6.04M | -3.54M | -6.60M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 10.00M | 0.00 | 11.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.60M | 257.00K | 2.24M | 1.30M | 1.94M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.60M | 257.00K | 12.24M | 1.30M | 12.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -842.00K | -3.61M | 6.20M | -2.25M | 6.34M |